Equities

Neurosense Therapeutics Ltd

NRSN:NAQ

Neurosense Therapeutics Ltd

Actions
  • Price (USD)1.32
  • Today's Change0.08 / 6.45%
  • Shares traded466.32k
  • 1 Year change-10.20%
  • Beta--
Data delayed at least 15 minutes, as of Jul 03 2024 18:00 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

NeuroSense Therapeutics Ltd is an Israel-based clinical-stage pharmaceutical company. The Company is active in field of drug development and treatment offers Amyotrophic Lateral Sclerosis (ALS) patients, as well as other neurodegenerative diseases. The Company's lead product candidate, PrimeC, is an oral formulation of a fixed dose combination composed of a specific ratio of drugs. In addition to PrimeC, the Company has initiated research and development efforts in Alzheimer's disease and Parkinson's disease

  • Revenue in USD (TTM)0.00
  • Net income in USD-11.88m
  • Incorporated2017
  • Employees16.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Unity Biotechnology Inc0.00-34.78m21.66m19.00--0.9027-----2.33-2.330.001.430.00----0.00-40.18-47.21-48.47-53.51-------6,395.92----0.00---100.00--10.36---61.28--
AIM ImmunoTech Inc193.00k-31.12m21.93m26.00--4.66--113.62-0.637-0.6370.0040.0960.0072--0.21897,423.08-116.00-45.64-148.40-48.3574.09-231.75-16,123.32-11,695.01----0.3478--43.26-11.26-48.94--35.73--
Minerva Neurosciences Inc0.00-31.60m21.96m9.00---------4.48-4.480.00-5.230.00----0.00-61.90-49.89-65.32-52.39-------442.65------------6.55------
Vincerx Pharma Inc0.00-38.25m22.15m42.00---------1.79-1.790.00-0.0290.00----0.00-130.68---205.70----------------------36.24------
Biora Therapeutics Inc544.00k-111.08m22.50m58.00------41.37-7.13-7.120.0267-3.290.0143--0.65949,379.31-291.43-122.84-482,965.20-369.01-----20,419.48-415.10---------98.69-87.44-154.63---53.68--
Spruce Biosciences Inc10.13m-46.75m23.25m22.00--0.349--2.30-1.15-1.150.24831.620.0894----349,206.90-41.26-41.24-50.47-46.49-----461.67-1,774.39---114.540.0423-------3.77------
Cocrystal Pharma Inc0.00-16.75m23.40m12.00--1.04-----1.65-1.650.002.220.00----0.00-52.03-50.94-56.92-52.77-------1,501.78----0.00------53.69--33.34--
Hcw Biologics Inc3.93m-27.39m23.45m45.00--2.68--5.97-0.7547-0.75470.10830.23110.1062--6.7987,258.22-74.07---97.78--29.61---697.59-----146.890.4863---57.72---67.74------
Neurosense Therapeutics Ltd0.00-11.88m23.81m16.00---------0.7299-0.72990.00-0.44880.00----0.00-350.36---5,244.59----------------------18.10------
Biomx Inc0.00-37.14m23.91m58.00---------0.6234-0.62340.000.38130.00----0.00-60.38---72.74-------------2.250.00------7.59------
Yubo International Biotech Ltd455.72k-1.26m23.98m18.00------52.61-0.0105-0.01050.0038-0.01720.24880.41265.2725,317.78-70.32------80.24---282.61--0.1487-4,023.75----479.86--0.8224------
Janone Inc0.00-18.58m24.16m5.00---------3.66-3.950.001.010.00----0.00-69.38-23.12-88.46-62.22--23.38---30.14----0.1264-------313.15------
Sol Gel Technologies Ltd1.72m-22.86m25.07m36.00--0.7679--14.58-0.8222-0.82220.06191.170.0387--0.515447,777.78-51.40-31.60-57.29-35.49-----1,329.13-135.76----0.00---59.9864.50-82.52---33.78--
Neurobo Pharmaceuticals Inc0.00-16.58m25.34m8.00--2.18-----3.26-3.260.002.050.00----0.00-68.36-95.57-108.01-135.64------------0.00------10.72--75.54--
BioVie Inc0.00-37.18m25.43m18.00--1.34-----0.9626-0.96260.000.31040.00----0.00-94.32-456.35-149.75-1,810.88------------0.2969-------92.67------
Data as of Jul 03 2024. Currency figures normalised to Neurosense Therapeutics Ltd's reporting currency: US Dollar USD

Institutional shareholders

1.18%Per cent of shares held by top holders
HolderShares% Held
Renaissance Technologies LLCas of 31 Mar 202471.10k0.41%
Meitav Mutual Funds Ltd.as of 31 Mar 202450.00k0.29%
Schiketanz Capital Advisors GmbHas of 29 Feb 202437.20k0.21%
Woodline Partners LPas of 31 Mar 202419.58k0.11%
Geode Capital Management LLCas of 31 Mar 202411.96k0.07%
UBS Securities LLCas of 31 Mar 202411.93k0.07%
Morgan Stanley Smith Barney LLC (Investment Management)as of 31 Mar 20241.50k0.01%
CWM LLCas of 31 Mar 20241.00k0.01%
Qube Research & Technologies Ltd.as of 31 Mar 202454.000.00%
Scientech Research LLCas of 31 Mar 20240.000.00%
More ▼
Data from 29 Feb 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.